Piramal Healthcare
Ali On Content / 12 Apr 2010
The scrips in this column have been recommended with a short-term investment horizon and carry high risk. So, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations
[INSERT_1]
Piramal Healthcare plans to acquire more drug brands and diagnostics chains to expand its footprint across India. The recent acquisition of emergency contraceptive brand i-Pill from Cipla for Rs 90 crore was a clear indication that the company is betting big on the domestic market. The company is also looking for more such over-the-counter (OTC) and established prescription drug brands for acquisition in the Indian market. The concerns in the contract research business that the company has faced in the last three quarters are likely to fade off. The inhalation anesthetic business is likely to witness a ramp from the first quarter of the next fiscal. In the recently ended quarter the FII holding has improved a bit compared to the September 2009 quarter. The Indian play in the company is likely to see some more aggressive plans ahead in order to increase its market share. The stock can be looked upon for both short and medium-term perspective.